Sana Raoof
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sana Raoof has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- A. Mark Fendrick
Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan
7 shared publications - Ali Tafazzoli
Grail, Inc., Menlo Park, California
7 shared publications - Anuraag R. Kansal
Grail, Inc., Menlo Park, USA
7 shared publications - Denise Zou
Surgical oncologist and research Director of Guatemala’s Cancer Institute (INCAN), Guatemala City, MD, Guatemala
7 shared publications - Walter Morris
University of Arkansas, Little Rock, AR
7 shared publications - Weicheng Ye
PPD Clinical Research Services, Thermo Fisher Scientific, Waltham, Massachusetts
7 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by Wiley in CA: A Cancer Journal for Clinicians
- Vol. 76 (6)
American Cancer Society guideline for the early detection of prostate cancer, 2026
The goal of prostate cancer screening is to reduce morbidity and mortality through the early detection of clinically significant disease. Accumulating evidence shows that prostate‐specific antigen (PSA)‐based screening significantly reduces prostate cancer mortality and advanced‐stage diagnosis, and approaches to reduce harms associated with screening are increasingly being used. The ACS conducted a systematic review and commissioned a modeling study to evaluate PSA‐based screening strategies, and concluded that the benefits of screening outweigh the harms. Before initiating screening, clinicians should ensure that patients are informed about the benefits, limitations, and harms of screening; the potential follow‐up evaluations of elevated PSA levels; and the expectation that low‐risk cancers will initially be managed with active surveillance. The ACS recommends biennial screening from ages 50‐69 years for average‐risk men (i.e., non‐Black men without a family history of prostate cancer). Annual screening from ages 45‐69 years is recommended for Black men. Annual screening from ages 45–69 years is recommended for non‐Black men with a strong family history (i.e., multiple first‐degree relatives diagnosed with prostate cancer at any age or one diagnosed before age 65 years). Biennial screening from ages 45‐69 years is recommended for non‐Black men with a single first‐degree relative diagnosed at age 65 years or older. For men ages 70–74 years, the balance of benefits and harms is uncertain, and individualized decision making is recommended. The ACS recommends further evaluating men ages 45–69 years with PSA levels ≥3.0 ng/mL and men ages 70–74 years with PSA levels ≥6.5 ng/mL. Most men who have elevated PSA levels confirmed on repeat testing should be offered magnetic resonance imaging and/or a validated biomarker test to guide biopsy decisions. Screening is not recommended for men with a life expectancy <10 years and should be discontinued at age 75 years.
- 12 November 2026
- Published by Wiley in CA: A Cancer Journal for Clinicians
- Vol. 76 (6)
Open AccessAmerican Cancer Society guideline for the early detection of prostate cancer, 2026
The goal of prostate cancer screening is to reduce morbidity and mortality through the early detection of clinically significant disease. Accumulating evidence shows that prostate‐specific antigen (PSA)‐based screening significantly reduces prostate cancer mortality and advanced‐stage diagnosis, and approaches to reduce harms associated with screening are increasingly being used. The ACS conducted a systematic review and commissioned a modeling study to evaluate PSA‐based screening strategies, and concluded that the benefits of screening outweigh the harms. Before initiating screening, clinicians should ensure that patients are informed about the benefits, limitations, and harms of screening; the potential follow‐up evaluations of elevated PSA levels; and the expectation that low‐risk cancers will initially be managed with active surveillance. The ACS recommends biennial screening from ages 50‐69 years for average‐risk men (i.e., non‐Black men without a family history of prostate cancer). Annual screening from ages 45‐69 years is recommended for Black men. Annual screening from ages 45–69 years is recommended for non‐Black men with a strong family history (i.e., multiple first‐degree relatives diagnosed with prostate cancer at any age or one diagnosed before age 65 years). Biennial screening from ages 45‐69 years is recommended for non‐Black men with a single first‐degree relative diagnosed at age 65 years or older. For men ages 70–74 years, the balance of benefits and harms is uncertain, and individualized decision making is recommended. The ACS recommends further evaluating men ages 45–69 years with PSA levels ≥3.0 ng/mL and men ages 70–74 years with PSA levels ≥6.5 ng/mL. Most men who have elevated PSA levels confirmed on repeat testing should be offered magnetic resonance imaging and/or a validated biomarker test to guide biopsy decisions. Screening is not recommended for men with a life expectancy <10 years and should be discontinued at age 75 years.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Molecular Cancer Signal Localization in MCED Testing Minimizes Radiation and Imaging Burden Compared with Whole-body Imaging Approaches
Efficient strategies for diagnostic evaluation of multicancer early detection (MCED) tests are needed to distinguish true-positive from apparent false-positive (FP) test results. Extending a previously published model, we compared 2 post–positive MCED test diagnostic evaluation strategies: a cancer signal origin (CSO)–guided approach with repeat MCED testing to resolve FPs (CSO-retest strategy) versus a whole-body imaging (WBI)–only strategy employing whole-body computed tomography (WBCT) followed by positron emission tomography (PET)/CT scans to resolve FPs. Analyses evaluated 2 scenarios with different test performance characteristics and specificities, with a number of imaging procedures required and radiation exposure for each strategy as outcomes measures. The CSO-retest strategy resulted in 10- to 20-fold reduction in the use of WBCT/PET/CT versus the WBI-only strategy across both scenarios. A 1% reduction in WBI-only test specificity from 99.5% to 98.5% led to a >3-fold increase in FPs and more than doubled WBI requirements. Estimated radiation exposure for initial diagnostic evaluations for the CSO-retest strategy were 0 to 26.1 millisieverts (mSv), whereas all initial diagnostic evaluations for the WBI-only strategy carried an obligatory exposure of 28 mSv. For the 50% of CSO predictions requiring initial imaging, dose exposure ranged from 0.28 mSv (mammography) to 26.1 mSv (triple-phase renal CT), or 1% to 93% of the dose required for the WBI-only strategy. The results suggest that CSO-guided diagnostic strategies incorporating targeted workups and MCED retesting markedly reduce radiation exposure compared with a WBI-only approach, and small changes in MCED test specificity lead to significantly more unnecessary workups.Prevention Relevance:Using MCED tests with molecular CSO prediction and MCED retesting to resolve apparent FPs enables targeted evaluations via existing diagnostic pathways, reducing radiation exposure compared with MCED tests without this feature that rely on WBI. These findings have important implications for MCED implementation including safety, cost, and accessibility.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Molecular Cancer Signal Localization in MCED Testing Minimizes Radiation and Imaging Burden Compared with Whole-body Imaging Approaches
Efficient strategies for diagnostic evaluation of multicancer early detection (MCED) tests are needed to distinguish true-positive from apparent false-positive (FP) test results. Extending a previously published model, we compared 2 post–positive MCED test diagnostic evaluation strategies: a cancer signal origin (CSO)–guided approach with repeat MCED testing to resolve FPs (CSO-retest strategy) versus a whole-body imaging (WBI)–only strategy employing whole-body computed tomography (WBCT) followed by positron emission tomography (PET)/CT scans to resolve FPs. Analyses evaluated 2 scenarios with different test performance characteristics and specificities, with a number of imaging procedures required and radiation exposure for each strategy as outcomes measures. The CSO-retest strategy resulted in 10- to 20-fold reduction in the use of WBCT/PET/CT versus the WBI-only strategy across both scenarios. A 1% reduction in WBI-only test specificity from 99.5% to 98.5% led to a >3-fold increase in FPs and more than doubled WBI requirements. Estimated radiation exposure for initial diagnostic evaluations for the CSO-retest strategy were 0 to 26.1 millisieverts (mSv), whereas all initial diagnostic evaluations for the WBI-only strategy carried an obligatory exposure of 28 mSv. For the 50% of CSO predictions requiring initial imaging, dose exposure ranged from 0.28 mSv (mammography) to 26.1 mSv (triple-phase renal CT), or 1% to 93% of the dose required for the WBI-only strategy. The results suggest that CSO-guided diagnostic strategies incorporating targeted workups and MCED retesting markedly reduce radiation exposure compared with a WBI-only approach, and small changes in MCED test specificity lead to significantly more unnecessary workups.Prevention Relevance:Using MCED tests with molecular CSO prediction and MCED retesting to resolve apparent FPs enables targeted evaluations via existing diagnostic pathways, reducing radiation exposure compared with MCED tests without this feature that rely on WBI. These findings have important implications for MCED implementation including safety, cost, and accessibility.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Molecular Cancer Signal Localization in MCED Testing Minimizes Radiation and Imaging Burden Compared with Whole-body Imaging Approaches
Supplementary Figure S3. Distribution of real-world CSO predictions.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Molecular Cancer Signal Localization in MCED Testing Minimizes Radiation and Imaging Burden Compared with Whole-body Imaging Approaches
Supplementary Figure S3. Distribution of real-world CSO predictions.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Molecular Cancer Signal Localization in MCED Testing Minimizes Radiation and Imaging Burden Compared with Whole-body Imaging Approaches
Supplementary Figure S2. Effective reduction in WBI for retesting over all PPV and CSO accuracy values, using maximal imaging in the CSO driven pathway and point estimates.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Molecular Cancer Signal Localization in MCED Testing Minimizes Radiation and Imaging Burden Compared with Whole-body Imaging Approaches
Supplementary Figure S2. Effective reduction in WBI for retesting over all PPV and CSO accuracy values, using maximal imaging in the CSO driven pathway and point estimates.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Molecular Cancer Signal Localization in MCED Testing Minimizes Radiation and Imaging Burden Compared with Whole-body Imaging Approaches
Supplementary Figure S1. Tests used along each diagnostic path, per positive individual.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Molecular Cancer Signal Localization in MCED Testing Minimizes Radiation and Imaging Burden Compared with Whole-body Imaging Approaches
Supplementary Figure S1. Tests used along each diagnostic path, per positive individual.
- Open Access
- 17 April 2026
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 19 (6) , 353-360
Molecular Cancer Signal Localization in MCED Testing Minimizes Radiation and Imaging Burden Compared with Whole-body Imaging Approaches
Efficient strategies for diagnostic evaluation of multicancer early detection (MCED) tests are needed to distinguish true-positive from apparent false-positive (FP) test results. Extending a previously published model, we compared 2 post–positive MCED test diagnostic evaluation strategies: a cancer signal origin (CSO)–guided approach with repeat MCED testing to resolve FPs (CSO-retest strategy) versus a whole-body imaging (WBI)–only strategy employing whole-body computed tomography (WBCT) followed by positron emission tomography (PET)/CT scans to resolve FPs. Analyses evaluated 2 scenarios with different test performance characteristics and specificities, with a number of imaging procedures required and radiation exposure for each strategy as outcomes measures. The CSO-retest strategy resulted in 10- to 20-fold reduction in the use of WBCT/PET/CT versus the WBI-only strategy across both scenarios. A 1% reduction in WBI-only test specificity from 99.5% to 98.5% led to a >3-fold increase in FPs and more than doubled WBI requirements. Estimated radiation exposure for initial diagnostic evaluations for the CSO-retest strategy were 0 to 26.1 millisieverts (mSv), whereas all initial diagnostic evaluations for the WBI-only strategy carried an obligatory exposure of 28 mSv. For the 50% of CSO predictions requiring initial imaging, dose exposure ranged from 0.28 mSv (mammography) to 26.1 mSv (triple-phase renal CT), or 1% to 93% of the dose required for the WBI-only strategy. The results suggest that CSO-guided diagnostic strategies incorporating targeted workups and MCED retesting markedly reduce radiation exposure compared with a WBI-only approach, and small changes in MCED test specificity lead to significantly more unnecessary workups. Prevention Relevance: Using MCED tests with molecular CSO prediction and MCED retesting to resolve apparent FPs enables targeted evaluations via existing diagnostic pathways, reducing radiation exposure compared with MCED tests without this feature that rely on WBI. These findings have important implications for MCED implementation including safety, cost, and accessibility.
- 17 April 2026
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 19 (6) , 353-360
Open AccessMolecular Cancer Signal Localization in MCED Testing Minimizes Radiation and Imaging Burden Compared with Whole-body Imaging Approaches
Efficient strategies for diagnostic evaluation of multicancer early detection (MCED) tests are needed to distinguish true-positive from apparent false-positive (FP) test results. Extending a previously published model, we compared 2 post–positive MCED test diagnostic evaluation strategies: a cancer signal origin (CSO)–guided approach with repeat MCED testing to resolve FPs (CSO-retest strategy) versus a whole-body imaging (WBI)–only strategy employing whole-body computed tomography (WBCT) followed by positron emission tomography (PET)/CT scans to resolve FPs. Analyses evaluated 2 scenarios with different test performance characteristics and specificities, with a number of imaging procedures required and radiation exposure for each strategy as outcomes measures. The CSO-retest strategy resulted in 10- to 20-fold reduction in the use of WBCT/PET/CT versus the WBI-only strategy across both scenarios. A 1% reduction in WBI-only test specificity from 99.5% to 98.5% led to a >3-fold increase in FPs and more than doubled WBI requirements. Estimated radiation exposure for initial diagnostic evaluations for the CSO-retest strategy were 0 to 26.1 millisieverts (mSv), whereas all initial diagnostic evaluations for the WBI-only strategy carried an obligatory exposure of 28 mSv. For the 50% of CSO predictions requiring initial imaging, dose exposure ranged from 0.28 mSv (mammography) to 26.1 mSv (triple-phase renal CT), or 1% to 93% of the dose required for the WBI-only strategy. The results suggest that CSO-guided diagnostic strategies incorporating targeted workups and MCED retesting markedly reduce radiation exposure compared with a WBI-only approach, and small changes in MCED test specificity lead to significantly more unnecessary workups. Prevention Relevance: Using MCED tests with molecular CSO prediction and MCED retesting to resolve apparent FPs enables targeted evaluations via existing diagnostic pathways, reducing radiation exposure compared with MCED tests without this feature that rely on WBI. These findings have important implications for MCED implementation including safety, cost, and accessibility.
- Open Access
- 11 February 2026
- Published by Elsevier in JTO Clinical and Research Reports
- Vol. 7 (5)
Outcomes and Toxicities of Definitive Radiation Therapy for Unresected Thymic Malignancies
- 11 February 2026
- Published by Elsevier in JTO Clinical and Research Reports
- Vol. 7 (5)
Open AccessOutcomes and Toxicities of Definitive Radiation Therapy for Unresected Thymic Malignancies
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Impact of Population Cancer Risk on the Cost-effectiveness of Multicancer Early Detection Testing in the United States
Supplementary Table 4: Weighted IRRs for Overall HCS Population and Gene Mutation Groupings by Cancer Type
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Impact of Population Cancer Risk on the Cost-effectiveness of Multicancer Early Detection Testing in the United States
Supplementary Table 4: Weighted IRRs for Overall HCS Population and Gene Mutation Groupings by Cancer Type
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Impact of Population Cancer Risk on the Cost-effectiveness of Multicancer Early Detection Testing in the United States
Supplementary Table 3: Cancer Risk by Gene Mutations and The Associated Risk of Cancer in The General Population
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Impact of Population Cancer Risk on the Cost-effectiveness of Multicancer Early Detection Testing in the United States
Supplementary Table 3: Cancer Risk by Gene Mutations and The Associated Risk of Cancer in The General Population
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Impact of Population Cancer Risk on the Cost-effectiveness of Multicancer Early Detection Testing in the United States
Supplementary Table 5: Sensitivity of MCED by Cancer Type and Stage
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Impact of Population Cancer Risk on the Cost-effectiveness of Multicancer Early Detection Testing in the United States
Supplementary Table 5: Sensitivity of MCED by Cancer Type and Stage